オプションチェーンは、2seventy bioの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、2seventy bioの市場センチメントを評価します。.

2seventy bio (NASDAQ:TSVT) 株価情報, オプションチェーン

2seventy bio

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.

2seventy bio Inc

News

Guidance

ABM Indus Raised The Lower End Of Its FY25 Adjusted EPS Outlook By $0.05, Now Expecting Adjusted EPS To Range From $3.65 To $3.80 Vs. Cons. Of $3.73

PWNX

Prestige Wealth's InnoSphere Tech Subsidiary Integrates DeepSeek

WIIM

OPRX

OptimizeRx shares are trading higher after the company reported better-than-expected Q4 earnings and sales.

TRNR

Interactive Strength shares are trading higher after the company secured $3.6 million in 3-year notes from an institutional investor, following a $2.9 million investment.

Stifel analyst Brian Brophy maintains Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) with a Buy and raises the price target from $102 to $103.

Price Target

Analyst Ratings

Stifel Maintains Buy on Limbach Holdings, Raises Price Target to $103

Telsey Advisory Group analyst Dana Telsey maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Market Perform and lowers the price target from $13 to $10.

Telsey Advisory Group Maintains Market Perform on Kohl's, Lowers Price Target to $10

Stifel analyst Jim Duffy maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Hold and lowers the price target from $240 to $226.

Stifel Maintains Hold on Dick's Sporting Goods, Lowers Price Target to $226

HC Wainwright &amp; Co. analyst Yi Chen maintains LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) with a Buy and raises the price target from $12 to $14.

LFMD

HC Wainwright & Co. Maintains Buy on LifeMD, Raises Price Target to $14

ONDS

Ondas Sees FY25 Revenue Of $25M Vs. $33.44M Est.

Ondas Posts Q4 Net Loss Of $10.3M Versus $14.1M In Q4 FY23

HC Wainwright &amp; Co. analyst Yi Chen maintains Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) with a Buy and lowers the price target from $17 to $15.

ZYXI

HC Wainwright & Co. Maintains Buy on Zynex, Lowers Price Target to $15

Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) reported quarterly sales of $7.19 million which beat the analyst consensus estimate of $5.75 million by 25.08 percent. This is a 44.97 percent increase over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Ondas Holdings Q4 Sales $7.19M Beat $5.75M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

Reiteration

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) with a Outperform and maintains $2 price target.

GROV

Telsey Advisory Group Maintains Outperform on Grove Collaborative Hldgs, Maintains $2 Price Target

Sprinklr Sees FY26 Revenues Between $821.5M-$823.5M Vs. $819.73M Estimate, With Adjusted EPS Of $0.38-$0.39 Vs. $0.38 Estimate

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Sprinklr Sees Q1 Revenues Between $201.5M-$202.5M Vs. $200.41M Estimate, With Adjusted EPS Of $0.10 Vs. $0.08 Estimate

The chairperson of Alibaba Group Holding ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Joseph Tsai acknowledged that everyone around the world is concerned about the ongoing tariff battle between the economic powerhouses of the world.
What Happened: While speaking at CNBC&#8217;s event Converge Live, in Singapore, Tsai responded to a question on tariff imposition by the Donald Trump administration and said that &#8220;Everyone is concerned about tariffs.&#8221;
He highlighted that the Chinese multinational technology company sells $50 billion worth of American products on its platform to Chinese consumers every year. On the other hand, about $30 billion worth of European products are also sold annually.
"I think the Trump administration will want to have more American companies doing business in China and making money there," he said, adding that it was ultimately between the global leaders to meet and decide on the future course of these protectionist policies.
Furthermore, he suggested if Trump&#8217;s wider tariff approach was just a bargaining chip, there was still a likelihood of seeing specific tariffs on Chinese electric vehicles. Tsai added that it could be a move to safeguard the American auto industry from potential competition.
See Also: <a href="https://www.benzinga.com/25/03/44269729/debt-over-equity-billionaire-howard-marks-endorses-credit-investments-amid-shifting-investor-focus-and-market-correction">Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: &#8216;Yields Implies Higher Returns From Credit Than The S&amp;P 500&#8217;</a>
Why It Matters: On Tuesday afternoon, President Trump unexpectedly reversed his decision to double tariffs on Canadian steel and aluminum to 50%, just hours after announcing the increase. The abrupt policy change, which rattled financial markets, followed Canada&#8217;s withdrawal of plans for a 25% surcharge on electricity.
Additionally, as Trump&#8217;s tariffs on steel and aluminum imports go into effect, the European Union announced on Wednesday that it will retaliate by imposing levies of 26 billion euros or $28.33 billion on U.S. goods beginning in April.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 0.73% to $560.00, and the QQQ also advanced 0.83% to $475.51, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44245897/billionaire-investor-ron-baron-reacts-to-nasdaq-sp-selloff-the-stock-prices-cant-believe-how-cheap-they-are" target="_blank" rel="noreferrer noopener">Billionaire Investor Ron Baron Reacts To Nasdaq, S&amp;P Selloff: ‘The Stock Prices…Can't Believe How Cheap They Are'</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Global

Economics

Markets

BABA

Alibaba's Joseph Tsai Says 'Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $75 to $50.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $50

United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) reported quarterly earnings of $0.01 per share. This is a 100.72 percent increase over losses of $(1.38) per share from the same period last year. The company reported $134.81 million in sales this quarter. This is a 15.39 percent increase over sales of $116.83 million the same period last year.

United Homes Gr Q4 EPS $0.01 Up From $(1.38) YoY, Sales $134.81M Up From $116.83M YoY

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

Comments

2seventy bio

2seventy bio (TSVT) オプション

2seventy bio (NASDAQ:TSVT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル